Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Lexaria Bioscience (NASDAQ:LEXX) has appointed Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson, a highly cited interventional cardiologist and Harvard Medical School researcher, will work directly with President John Docherty to expand applications of Lexaria's DehydraTECH drug delivery platform in GLP-1 and hypertension.
As CEO of the Baim and PERFUSE research institutes at Harvard Medical School, Dr. Gibson has led over 1,250 studies and 70 FDA submissions. His institutes have published 5,500 manuscripts and operate across 7,000 sites in 57 countries. His research has been cited over 170,000 times, and he was named one of the Fifty Most Influential Voices in Healthcare by Medika Life in 2021.
Lexaria Bioscience (NASDAQ:LEXX) ha nominato il Dr. Michael Gibson come nuovo Chief Medical Advisor. Il Dr. Gibson, un cardiologo interventista di spicco e ricercatore della Harvard Medical School, lavorerà direttamente con il Presidente John Docherty per espandere le applicazioni della piattaforma di somministrazione dei farmaci DehydraTECH di Lexaria in GLP-1 e ipertensione.
In qualità di CEO degli istituti di ricerca Baim e PERFUSE presso la Harvard Medical School, il Dr. Gibson ha guidato oltre 1.250 studi e 70 sottomissioni all'FDA. I suoi istituti hanno pubblicato 5.500 manoscritti e operano in 7.000 sedi in 57 paesi. La sua ricerca è stata citata oltre 170.000 volte ed è stato nominato una delle Cinquanta Voci più Influenziali nella Sanità da Medika Life nel 2021.
Lexaria Bioscience (NASDAQ:LEXX) ha nombrado al Dr. Michael Gibson como su nuevo Chief Medical Advisor. El Dr. Gibson, un cardiólogo intervencionista muy citado y investigador de la Harvard Medical School, trabajará directamente con el Presidente John Docherty para expandir las aplicaciones de la plataforma de entrega de medicamentos DehydraTECH de Lexaria en GLP-1 e hipertensión.
Como CEO de los institutos de investigación Baim y PERFUSE en la Harvard Medical School, el Dr. Gibson ha dirigido más de 1,250 estudios y 70 presentaciones a la FDA. Sus institutos han publicado 5,500 manuscritos y operan en 7,000 sitios en 57 países. Su investigación ha sido citada más de 170,000 veces y fue nombrado una de las Cincuenta Voces más Influyentes en Salud por Medika Life en 2021.
렉사리아 바이오사이언스 (NASDAQ:LEXX)가 마이클 기브슨 박사를 새로운 최고 의학 고문으로 임명했습니다. 기브슨 박사는 하버드 의대의 저명한 심장전문외과 의사이자 연구자로, GLP-1 및 고혈압에 대한 렉사리아의 DehydraTECH 약물 전달 플랫폼의 응용 확대를 위해 존 도체르티 사장과 직접 협력할 것입니다.
하버드 의대의 Baim 및 PERFUSE 연구소의 CEO인 기브슨 박사는 1,250건 이상의 연구와 70건의 FDA 제출을 이끌어 왔습니다. 그의 연구소는 5,500개의 논문을 출판했으며 57개 국가의 7,000개 장소에서 운영되고 있습니다. 그의 연구는 170,000회 이상 인용되었으며, 2021년 Medika Life에서 의료 분야의 50대 영향력 있는 목소리 중 하나로 선정되었습니다.
Lexaria Bioscience (NASDAQ:LEXX) a nommé le Dr. Michael Gibson comme son nouveau Chief Medical Advisor. Le Dr. Gibson, un cardiologue interventionnel très cité et chercheur à la Harvard Medical School, travaillera directement avec le Président John Docherty pour élargir les applications de la plateforme de délivrance de médicaments DehydraTECH de Lexaria dans GLP-1 et l'hypertension.
En tant que PDG des instituts de recherche Baim et PERFUSE à la Harvard Medical School, le Dr. Gibson a dirigé plus de 1.250 études et 70 soumissions à la FDA. Ses instituts ont publié 5.500 manuscrits et opèrent sur 7.000 sites dans 57 pays. Sa recherche a été citée plus de 170.000 fois et il a été nommé l'une des cinquante voix les plus influentes dans le domaine de la santé par Medika Life en 2021.
Lexaria Bioscience (NASDAQ:LEXX) hat Dr. Michael Gibson als neuen Chief Medical Advisor ernannt. Dr. Gibson, ein hochzitiertet interventioneller Kardiologe und Forscher an der Harvard Medical School, wird direkt mit Präsident John Docherty zusammenarbeiten, um die Anwendungen von Lexarias DehydraTECH-Arzneimittellieferplattform in GLP-1 und Bluthochdruck auszubauen.
Als CEO der Forschungsinstitute Baim und PERFUSE an der Harvard Medical School hat Dr. Gibson über 1.250 Studien und 70 FDA-Einreichungen geleitet. Seine Institute haben 5.500 Manuskripte veröffentlicht und arbeiten an 7.000 Standorten in 57 Ländern. Seine Forschung wurde über 170.000 Mal zitiert, und 2021 wurde er von Medika Life als eine der fünfzig einflussreichsten Stimmen im Gesundheitswesen ausgezeichnet.
- Appointment of highly credentialed Harvard Medical School professor strengthens scientific leadership
- Addition of expertise in cardiovascular research and FDA submissions enhances drug development capabilities
- Strategic expansion into GLP-1 and hypertension markets with experienced advisor
- None.
Insights
Dr. Gibson's appointment as Chief Medical Advisor represents a significant strategic enhancement to Lexaria's scientific capabilities, particularly in cardiovascular research and drug delivery optimization. His extensive experience with FDA submissions and clinical trials, including work with major cardiovascular drugs, aligns perfectly with Lexaria's focus on DehydraTECH's applications in GLP-1 and hypertension treatments. Dr. Gibson's proven track record in leading over 1,250 studies and publishing 5,500 manuscripts demonstrates the caliber of expertise being brought to Lexaria's drug delivery platform development.
The appointment could accelerate Lexaria's research initiatives and potentially streamline the regulatory pathway for DehydraTECH applications. His network of 7,000 research sites across 57 countries could facilitate faster and more comprehensive clinical trials for Lexaria's technology. Additionally, his expertise in cardiology and drug development could be instrumental in optimizing DehydraTECH for cardiovascular applications.
Dr. Gibson joining Lexaria's new scientific advisor board
KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.
C. Michael Gibson M.S., M.D., is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. Gibson founded PERFUSE in 1987 which served as the TIMI Data coordinating center that coordinated data for the first 50 TIMI trials. The Baim institute was formerly known as Harvard Clinical Research Institute and was founded in 2000.
The combined institutes have led over 1,250 studies, published 5,500 manuscripts in peer review literature (including 144 in the New England Journal of Medicine) and have led 70 FDA submissions from their network of 7,000 sites in 57 countries worldwide. Since 2014, Gibson has consistently been ranked as one of the world's most highly cited authors in all of science by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 170,000 times.
"Lexaria's drug delivery technology offers exciting new pathways towards improving pharmacokinetic drug performance that could unlock a new era of reduced drug waste and adverse side effects combined with enhanced efficacy," said Dr. Gibson. "I'm excited to pursue new and improved applications for this exciting technology."
"Dr. Gibson has a wealth of knowledge and experience that will benefit Lexaria, particularly in the area of hypertension which remains an area of intense interest for Lexaria," said John Docherty, President. "On behalf of everyone at Lexaria, I welcome Dr. Gibson's contributions as our new Chief Medial Advisor and member of our scientific advisory board."
As Chief Medical Advisor, Dr. Gibson will participate with other scientific and medical experts within Lexaria's newly-formed scientific advisory board in pursuing Lexaria's prioritized objectives in the fields of drug delivery optimization.
Dr. Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 34,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack. He founded WikiDoc.org and WikiPatient.org and is Editor-In-Chief of over 2,200 active contributors who have edited the content of over 100,000 chapters millions of times over the past 15 years. Gibson also founded www.clinicaltrialresults.org. Gibson serves as Chief Medical Correspondent for the American College of Cardiology. Gibson has over 435,000 followers on social media where he is a leading influencer, second only to Sanjay Gupta in some polls
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
FAQ
What is Dr. Michael Gibson's role at Lexaria Bioscience (LEXX)?
How many studies and FDA submissions has LEXX's new advisor Dr. Gibson led?
What therapeutic areas will LEXX focus on with Dr. Gibson's guidance?
What is Dr. Gibson's research impact in the medical field?
